This study randomized 3514 patients to a thin-strut biodegradable polymer everolimus-eluting stent (SYNERGY) vs. a sirolimus-eluting stent (ORSIRO) vs. a durable polymer zotarolimus-eluting stent (RESOLUTE INTEGRITY).
The combined endpoint, the rate of target vessel failure, was similar for all three devices (8.3% for the zotarolimos-eluting stent, 6.8% for the everolimus-eluting stent, and 6.6% for the sirolimus-eluting stent).
Landmark analyses at one year had revealed an advantage in favor of new devices as regards the rates of revascularization and other secondary endpoints. However, at the two-year follow-up, these differences were leveled out.
Original title: Two-Year Clinical Outcome of All-Comers Treated with Three Highly Dissimilar Contemporary Coronary Drug-Eluting Stents in the Randomized BIO-RESORT Trial.
Presenter: Marlies M. Kok.
Subscribe to our weekly newsletter
Get the latest scientific articles on interventional cardiology
We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.